Botanix Pharmaceuticals Limited (ASX:BOT)
Australia
· Delayed Price · Currency is AUD 0.0540
-0.0030 (-5.26%)
Mar 9, 2026, 4:11 PM AEST
Botanix Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Operating Revenue | 21.92 | 5.79 | 2.07 | 3.77 | 2.75 | 6.88 | Upgrade
|
| Other Revenue | - | - | - | - | - | 0.01 | Upgrade
|
| Revenue | 21.92 | 5.79 | 2.07 | 3.77 | 2.75 | 6.89 | Upgrade
|
| Revenue Growth (YoY) | 959.24% | 179.74% | -45.14% | 36.94% | -60.00% | -9.07% | Upgrade
|
| Cost of Revenue | 8.52 | 3.77 | 3.65 | 5.73 | 10.29 | 6.57 | Upgrade
|
| Gross Profit | 13.39 | 2.02 | -1.58 | -1.96 | -7.54 | 0.32 | Upgrade
|
| Selling, General & Admin | 79.35 | 62.15 | 7.94 | 4.41 | 4.28 | 2.62 | Upgrade
|
| Other Operating Expenses | - | - | - | 1.13 | 0.89 | 0.41 | Upgrade
|
| Operating Expenses | 97.96 | 84.93 | 12.41 | 7.17 | 5.65 | 3.7 | Upgrade
|
| Operating Income | -84.56 | -82.91 | -13.99 | -9.13 | -13.19 | -3.38 | Upgrade
|
| Interest Expense | -6.94 | -5.37 | -0.01 | -0.08 | -0.04 | -0.06 | Upgrade
|
| Interest & Investment Income | 1.4 | 1.88 | 0.08 | 0.07 | 0.04 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.03 | 0.01 | 0.06 | -0.01 | 0.02 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.37 | - | - | - | - | - | Upgrade
|
| Pretax Income | -88.7 | -86.4 | -13.87 | -9.15 | -13.17 | -3.33 | Upgrade
|
| Net Income | -88.7 | -86.4 | -13.87 | -9.15 | -13.17 | -3.33 | Upgrade
|
| Net Income to Common | -88.7 | -86.4 | -13.87 | -9.15 | -13.17 | -3.33 | Upgrade
|
| Shares Outstanding (Basic) | 1,919 | 1,845 | 1,502 | 1,154 | 973 | 973 | Upgrade
|
| Shares Outstanding (Diluted) | 1,919 | 1,845 | 1,502 | 1,154 | 973 | 973 | Upgrade
|
| Shares Change (YoY) | 13.48% | 22.87% | 30.12% | 18.58% | 0.02% | 3.91% | Upgrade
|
| EPS (Basic) | -0.05 | -0.05 | -0.01 | -0.01 | -0.01 | -0.00 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.05 | -0.01 | -0.01 | -0.01 | -0.00 | Upgrade
|
| Free Cash Flow | -78.49 | -78.87 | -8.24 | -12.08 | -11.19 | -2.98 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -0.04 | -0.01 | -0.01 | -0.01 | -0.00 | Upgrade
|
| Gross Margin | 61.11% | 34.85% | -76.48% | -51.83% | -273.62% | 4.58% | Upgrade
|
| Operating Margin | -385.82% | -1432.24% | -676.11% | -241.93% | -478.66% | -49.08% | Upgrade
|
| Profit Margin | -404.72% | -1492.37% | -670.20% | -242.66% | -478.10% | -48.41% | Upgrade
|
| Free Cash Flow Margin | -358.13% | -1362.39% | -398.17% | -320.27% | -406.24% | -43.21% | Upgrade
|
| EBITDA | -82.23 | -80.65 | -13.92 | -9.11 | -13.17 | -3.36 | Upgrade
|
| EBITDA Margin | - | - | - | -241.38% | - | -48.84% | Upgrade
|
| D&A For EBITDA | 2.33 | 2.26 | 0.07 | 0.02 | 0.02 | 0.02 | Upgrade
|
| EBIT | -84.56 | -82.91 | -13.99 | -9.13 | -13.19 | -3.38 | Upgrade
|
| EBIT Margin | - | - | - | -241.93% | - | -49.08% | Upgrade
|
| Revenue as Reported | - | - | - | - | 2.79 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.